Immunotherapy in urothelial carcinoma: fade or future standard?
نویسندگان
چکیده
Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.
منابع مشابه
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate c...
متن کاملRenal Capillary Hemangioma Mimicking Urothelial Carcinoma, A Case Report and Review of the Literature
Renal hemangioma is a rare tumor which can be capillary or cavernous. There have been less than 30 renal capillary hemangioma cases reported in the English literature. Herein we will report a case of renal hemangioma which was detected in a 74-year-old man operated with the impression of urothelial carcinoma of hilum.
متن کاملSpotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpo...
متن کاملگزارش یک مورد سرطان اوروتلیال پلاسماسیتوئید مثانه
Bladder cancer most commonly exists as an epithelial tumor in which around 90% of cases are transitional cell carcinoma (TCC) with a papillary appearance. The world health organization (WHO) classification defines new histological and molecular variants of urothelial carcinoma in 2004. One of them is plasmacytoid urothelial carcinoma (PUC). Less than 100 cases have been reported in the literatu...
متن کاملRole of FGFR3 in Urothelial Carcinoma
Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...
متن کامل